Bayer Aktiengesellschaft (BAYRY)
OTCMKTS
· Delayed Price · Currency is USD
6.44
-0.33 (-4.87%)
Nov 6, 2024, 2:00 PM EST
Bayer Aktiengesellschaft Revenue
Bayer Aktiengesellschaft had revenue of 11.14B EUR in the quarter ending June 30, 2024, with 0.91% growth. This brings the company's revenue in the last twelve months to 47.11B, down -3.29% year-over-year. In the year 2023, Bayer Aktiengesellschaft had annual revenue of 47.64B, down -6.11%.
Revenue (ttm)
47.11B EUR
Revenue Growth
-3.29%
P/S Ratio
n/a
Revenue / Employee
486.05K EUR
Employees
96,931
Market Cap
25.25B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 47.64B | -3.10B | -6.11% |
| Dec 31, 2022 | 50.74B | 6.66B | 15.10% |
| Dec 31, 2021 | 44.08B | 2.68B | 6.48% |
| Dec 31, 2020 | 41.40B | -2.15B | -4.93% |
| Dec 31, 2019 | 43.55B | 6.80B | 18.52% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sandoz Group AG | 10.11B |
| Telix Pharmaceuticals Limited | 430.80M |
| Elekta AB (publ) | 1.69B |
| Ryman Healthcare Limited | 411.39M |
| Verano Holdings Corp. | 920.97M |
| Vireo Growth Inc. | 98.04M |
| Medexus Pharmaceuticals Inc. | 108.78M |
Bayer Aktiengesellschaft News
- 7 days ago - Bayer and Liveo Research Launch First-of-its-Kind Blister Packaging with Improved Environmental Footprint - Business Wire
- 22 days ago - Bayer submits EU marketing application for menopause relief drug - Reuters
- 23 days ago - Bayer Seeks European Approval For Third Indication For Cancer Drug Darolutamide - Benzinga
- 23 days ago - Bayer applies for third indication of Nubeqa in EU - Reuters
- 23 days ago - Orion's collaboration partner Bayer submits application for third indication of darolutamide in the EU - GlobeNewsWire
- 26 days ago - Bayer must pay $78 mln in latest Roundup cancer trial, jury finds - Reuters
- 27 days ago - Bayer shares fall 7% as US court reconsiders Monsanto PCB exposure case - Invezz
- 4 weeks ago - Bayer plunges after U.S. court accepts review of Washington PCB case - Seeking Alpha